


## Exisulind

<b>Cat. No.:</b>	HY-13633		
<b>CAS No.:</b>	59864-04-9		
<b>Molecular Formula:</b>	C <sub>20</sub> H <sub>17</sub> FO <sub>4</sub> S		
<b>Molecular Weight:</b>	372.41		
<b>Target:</b>	Aldose Reductase		
<b>Pathway:</b>	Metabolic Enzyme/Protease		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (268.52 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	2.6852 mL	13.4261 mL	26.8521 mL
5 mM	0.5370 mL	2.6852 mL	5.3704 mL
10 mM	0.2685 mL	1.3426 mL	2.6852 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 1 mg/mL (2.69 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ 1 mg/mL (2.69 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

Exisulind is an inactive metabolite of the nonsteroidal, anti-inflammatory agent sulindac<sup>[1]</sup>. Exisulind inhibits aldose reductase with an IC<sub>50</sub> of 367 nM in vitro and may contribute to the beneficial pharmacological effects of sulindac on type 2 diabetic complications<sup>[2]</sup>.

### REFERENCES

- [1]. Kitamura S, Tatsumi K. In vitro metabolism of sulindac and sulindac sulfide: enzymatic formation of sulfoxide and sulfone. Jpn J Pharmacol. 1982 Oct;32(5):833-8.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA